Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They got caught off-guard by buyers! Not much sellers here. Now they're slowly putting downward pressure. We'll see what happens.
Power Hour coming....
CFGN is on the ASK (and bid .06)...first I've seen for diluting MMs
Terren S. Peizer
Founder, Chairman & CEO,Catasys, Inc.(Nasdaq:CATS)
Mr. Terren S. Peizer has been Chairman of BioVie Inc and also serves as its Chief Executive Officer and Director since July 3, 2018. He is Founder of Neurmedix, Inc. and serves as its Chairman and Chief Executive Officer. Mr. Peizer serves as Chairman and Managing Director at Crede CG II, Ltd. Mr. Peizer founded Catasys, Inc. (also known as Hythiam Inc.) in February 2003 and has been its Chairman and Chief Executive Officer since February 2003. He is Founder of Crede .
Board Members Memberships*
>>> Chairman and Managing Director
Crede CG II, Ltd.
>>> Founder, Chairman & CEO
Crede Capital Group LLC
>>> Founder, Chairman & CEO
Neurmedix, Inc.
>>> 2003-Present
Founder, Chairman & CEO
Catasys, Inc.
>>> 2018-Present
Chairman & CEO
BioVie Inc.
https://www.bloomberg.com/research/stocks/people/person.asp?personId=7337242&privcapId=7290234
BioVie is in good hands THIS TIME!!! imo
That's exactly what I've been doing the moment I found this gem. Slowly accumulating! The best strategy while not much is in the know about this company. Terren Peizer won't embarked in BIVI for nothing! imo
Follow what insider's are doing my friend.
They're buying $BIVI..
So, do we!
THE BEST PLAY USUALLY THE STOCK MOVES LIKE WATER!
...:)
Enjoy!
.50-$5.00 not if...??
But, when??
I say 2019 for sure imo.
Yup! Something is brewing?
$BIVI MAKING A MOVE AGAIN.
...:)
Definitely! Smart monies' pouring in!!!
GLTA
There is over $80k on the bid right now...something is in the works here.
Huh! same thing happening today. More large bids coming in. Now this is really getting serious with BIVI. Ask size is very thin and moves fast as slapping going on. A monumental event will definitely explode this low priced gem to dollarland, imo.
Haven't seen such large block bidding in this stock before. Smart money pouring in. Good sign! Wait when BIVI gets the attention it deserves. This is just the beginning. Heck, the clinical program is pretty much de-risked. This is extremely low priced, the most undervalued NASH related stock of them all! IMO.
GLTY
1milly on the bid now...shit is getting real here!
BIVI slow accumulation of shares continues!
BioVie is unbelievably way under-the-radar. It is the most undervalued NASH related stock you can find in the market. Mr. Terren Peizer saw the great potential of this company, not to mention Mallinckrodt's (MNK) interest on BioVie's Technology Platform, thus initiating a IP patent challenge with the USPTO which I think the deciding factor that led him to embark in this microcap company. Considering his profile, I believe BioVie is in good hands. All this in my opinion only.
GLTY
The chart is ready to move up another leg here...large bidders coming in the past two weeks too w/ increasing volume. Some with 200k share bids or more. Not much Twitter chatter on this one either...definitely flying under the radar.
Nice insider buying as of early Feb 2019...website looks professional.
https://www.biovieinc.com/investors/
If Terren has been a testament to CATS (Catasys) success thus far, I'd expect this company to perform as well! I've been in CATS since the end of 2017.
Won't be long here! Ride the ascending triangles...
BIVI 10Q For Period Ending December 31, 2018
Cash: $1,630,483
Total Other Assets: $2,015,003
TOTAL ASSETS: $3,645,486
Total Current Liabilities: $104,836
Total Long-Term Liabilities:$104,836
5. Renegotiated Debt
On July 19, 2018, Geis-Hides Consulting LLC entered into an Accord and Debt Satisfaction Agreement with the Company in which the consulting firm agreed to release the Company from all liabilities arising from the Original Contract and Debt Repayment Plan dated December 15, 2013 totaling $132,000 and received cash of $65,000 and 260,000 common shares in satisfaction. The common shares were valued at the market price on the date of settlement at $0.06 per common share. The gain of $51,400 on the settlement of debt was reflected on the Statements of Operations as “other income” for the six month period ended December 31, 2018.
6. Related Party Transactions
On July 9, 2018, Jonathan Adams (COO) entered into an Accord and Debt Satisfaction Agreement with the Company in which he agreed to release the Company from all liabilities including the original contract to defer payment of his accrued salary dated March 23, 2017, the promissory note issued by the Company to defer payment of accrued salary; and subsequent unpaid salary, totaling the amount of $534,722, and received cash of $25,694 in satisfaction. The gain of $509,028 on the settlement of debt was reflected in the additional paid in capital.
On August 8, 2018, Barrett Ehrlich (Independent contractor, related party to Elliot Ehrlich and shareholder) on behalf of The Barrett Edge Inc. (“Barrett”) entered into an Accord and Debt Satisfaction Agreement with the Company in which Barrett agreed to release the Company from all liabilities including the original contract to defer payment of accrued consulting fees dated March 23, 2017, the promissory note issued by the Company to defer payment of accrued consulting fees; loan to the Company for $14,000, and subsequent unpaid consulting fees, totaling $543,014, and received cash of $131,333 and 493,333 common shares in satisfaction. The common shares were valued at the market price on the date of settlement at $0.13 per common share. The gain of $361,548 on the settlement of debt was reflected in the additional paid in capital.
On July 9, 2018, Elliot Ehrlich (former CEO and shareholder) entered into an Accord and Debt Satisfaction Agreement with the Company in which he agreed to release the Company from all liabilities including the original contract to defer payment of accrued salary dated March 23, 2017, totaling the amount of $222,028 the promissory note issued by the Company to defer payment of accrued salary; and received cash of $22,203 and 222,028 common shares in satisfaction. The common shares were valued at the market price on the date of settlement at $0.06 per common share. The gain of $186,503 on the settlement of debt was reflected in the additional paid in capital.
Offerings of Common Stock and Warrants
On July 3, 2018, BioVie, Inc., the Company, entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Acuitas Group Holdings, LLC (“Acuitas”) and certain other purchasers identified in the Purchase Agreement (together with Acuitas, the “Purchasers”) pursuant to which (i) the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the Company’s newly created Series A Convertible Preferred Stock (the “Preferred Stock”) at a price per share of $1.50 per share of Preferred Stock (the “Initial Sale”) and (ii) the Company will issue associated warrants (the “Warrants”) to purchase 213,333,200 shares of the Company’s Class A Common Stock (the “Common Stock”), each subject to the terms and conditions set forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. The Company received $160,000 of the $3.2 million in April and May 2018 as prepaid equity. Acuitas also received an additional 833,333 Warrants in connection with the payoff of a note issued by the Company in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition, Acuitas has the option to purchase up to an additional 200,000,000 shares of Common Stock at a price per share of $0.015, and associated warrants on the same terms as the Warrants, within two weeks following the one year anniversary of the closing of the Initial Sale (the “Subsequent Sale”) in the event that the Company has not obtained $3,000,000 of funding through various non-dilutive grants prior to the one year anniversary of the closing of the Initial Sale.
Each share of Preferred Stock automatically converted into 100 shares of Common Stock upon the filing with the Secretary of State of the State of Nevada of a Certificate of Amendment to the Company’s Articles of Incorporation (the “Amendment”) on August 13, 2018 that increased the number of authorized shares of Common Stock to 800,000,000. The Amendment was approved by the written consent of the holders of more than a majority of the Company’s issued and outstanding Common Stock on July 3, 2018 and was filed with the Secretary of State of the State of Nevada 20 calendar days following the distribution of the Company’s Definitive Information that was filed with the Securities and Exchange Commission.
The purchase price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants, and the Common Stock in the Subsequent Sale is subject to adjustment. In the event that Mallinckrodt Pharmaceuticals Ireland Limited prevails in any proceeding which results in the useful life of the Company’s current intellectual property rights being reduced by more than 75 percent, then the price per share of Common Stock, the associated conversion ratio of the Preferred Stock, and the exercise price of the Warrants shall be retroactively adjusted to 50 percent of the then-effective price per share of Common Stock under the Purchase Agreement (for example, if the then-effective price per share of Common Stock is $0.015, then following such event, the price per share will be $0.0075). In this case, the Company may be required to issue additional shares of Common Stock, but in no event will the Company be required to pay cash, to reflect such lower price per share.
The Purchase Agreement contained customary representations and warranties. In connection with the disclosure schedule associated with the representations and warranties, the Company also disclosed customary information, including the following: (i) the existence of the Mallinckrodt Pharmaceuticals Ireland Limited petition before the US Patent Trial and Appeal Board, (ii) the current capitalization of the Company, (iii) the Company’s obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC and the Company, (iv) the Company’s obligation to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between the Company and the University of Padova (Italy), and (v) certain recent issuances of Common Stock by the Company.
Pursuant to the Purchase Agreement, Terren Peizer, the Chairman of Acuitas, was appointed as a member of the Company’s Board of Directors (the “Board”) and as the Chief Executive Officer of the Company, effective July 3, 2018. The issuance of the Preferred Stock, the Warrants and the underlying common stock under the Purchase Agreement is exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act.
https://www.sec.gov/Archives/edgar/data/1580149/000152013819000027/bivi-20181231_10q.htm
See....Almost 80%(including warrants when exercised) of the outstanding common shares are owned by the CEO Terren Peizer.
https://www.sec.gov/Archives/edgar/data/904534/000143774918012945/peit20180702_sc13d.htm
FYI... Acuitas Group Holdings is >>>HUGE!!!
Terren Peizer
International financier
Terren Scott Peizer, dubbed the "Zelig of Wall Street", is an International Financier and Chairman of Los Angeles-based investment company, Acuitas Group Holdings. Peizer is Founder and Chairman of the three Acuitas companies, and is CEO of Catasys, Inc. and Crede Capital Group. Wikipedia
Born: 1959 (age 60 years), Beachwood, OH
Education: Wharton School of the University of Pennsylvania
Organizations founded: Hythiam, Inc., Clearant
https://www.google.com/search?safe=strict&rlz=1C1AOHY_enUS708US708&ei=yBlmXLGDCo-80wKatL6oAg&q=acuitas+group+holdings&oq=acuitas+holdings&gs_l=psy-ab.1.0.0i7i30j0i13j0i7i30j0i13l7.18257.24103..27454...1.0..0.885.7976.3-2j6j5j2......0....1..gws-wiz.......0i71j0i131i67.LZGyZP7hg6I
The Mallinckrodt Pharmaceuticals Ireland Limited patent challenge clearly shows their great interest in Biovie's technology and that's most likely the deciding factor as to why TERREN PEIZER got himself onboard with BIOVIE,>>> seems he didn't care too much of Biovie's small net asset? IMO.
https://www.biovieinc.com/
Terren S. Peizer
Founder, Chairman & CEO,Catasys, Inc.
Mr. Terren S. Peizer has been Chairman of BioVie Inc and also serves as its Chief Executive Officer and Director since July 3, 2018. He is Founder of Neurmedix, Inc. and serves as its Chairman and Chief Executive Officer. Mr. Peizer serves as Chairman and Managing Director at Crede CG II, Ltd. Mr. Peizer founded Catasys, Inc. (also known as Hythiam Inc.) in February 2003 and has been its Chairman and Chief Executive Officer since February 2003. He is Founder of Crede .
Board Members Memberships*
>>> Chairman and Managing Director
Crede CG II, Ltd.
>>> Founder, Chairman & CEO
Crede Capital Group LLC
>>> Founder, Chairman & CEO
Neurmedix, Inc.
>>> 2003-Present
Founder, Chairman & CEO
Catasys, Inc.
>>> 2018-Present
Chairman & CEO
BioVie Inc.
https://www.bloomberg.com/research/stocks/people/person.asp?personId=7337242&privcapId=7290234
BIOVIE
Pioneering therapies for advanced liver disease
Non-confidential investor presentation | December 2018
***A new treatment option is emerging for refractory ascites
Based on investigative studies in Italy and Australia
***Terlipressin (BIV201’s active agent) is approved in 40+ countries for
treating related liver cirrhosis complications (HRS & BEV*)
***BIV201 is a new drug candidate in the US
Terlipressin is not available in the US or Japan
***Currently in US phase 2 clinical
trials; seeking to replicate
European & Australian
investigative study results
***BIV201 offers advantages in 40+ countries where
Terlipressin is already approved
Targeting improved efficacy and safety compared to IV bolus dosing
***Clinically de-risked development program
The same therapy that is currently in use in Italy and Australia
***US patent protection
through 2036
***Filed for patents in Japan,
China & Europe
***US Orphan Drug designations for
both ascites and HRS to enable 7
years of market exclusivity
***FDA Fast Track status; will seek
Breakthrough Therapy designation
https://www.biovieinc.com/wp-content/uploads/2019/01/BioVie-Non-Conf-Deck_Dec_2018.pdf
Mallinckrodt (NYSE:MNK)will make shareholders of Biovie(OTCQB:BIVI)very rich!
Challenge to US Patent
On April 30, 2018, the Company received notice that Mallinckrodt Pharmaceuticals Ireland Limited had petitioned the US Patent and Trademark Office (USPTO) to institute an Inter Partes Review of BioVie’s US Patent No. 9,655,945 titled “Treatment of Ascites” (the ‘945 patent). Inter Partes Review is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the patentability of one or more claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior art consisting of patents and printed publications.
On August 15, 2018, BioVie submitted a Preliminary Response to the PTAB providing a rationale as to why, in the Company’s opinion, Mallinckrodt’s request to institute the IPR should not be granted. On November 14, 2018, the PTAB granted institution of the IPR challenge after determining that there was a reasonable likelihood of success in proving that at least one of the Company’s 14 claims was unpatentable. BioVie will seek to defend the ‘945 patent and/or pursue a favorable settlement. As of December 31, 2018, no adjustments or accruals are reflected as the Company is unable to determine a likely outcome at this time.
https://www.sec.gov/Archives/edgar/data/1580149/000152013819000027/bivi-20181231_10q.htm
Only one claim if MNK succeeds isn't enough. I smell licensing deal here or buyout! Biovie (BIVI) is the most undervalued NASH related stock, IMO.
I don’t see anything in the filings to explain a run from .06 to .25 and all the way back to .08. I wonder if someone ran a promotion. The message board doesn’t show anything, pumping or otherwise. Still a mystery.
Bought some on the dip. They have a very professional web site.
http://www.biovieinc.com/
Read all the filings provided on Otc Markets and/or the ones posted here.
Congrats to those here who patiently held on.
What the heck is going on here. This sleepy one is waking up in a huge way. More than tripled since last week.
Yep! Got my initial position 3 weeks ago. Reaping gains!
You might want to keep an eye on MYMX as well!
GL
What do you think of this filings? TIA
BRIEF-BioVie says first patient dosed in trial for refractory ascites due to liver cirrhosis
REUTERS 6:15 AM ET 9/28/2017
Sept 28 (Reuters) - Biovie Inc(BIVI)
* BioVie(BIVI) announces first patient dosed with BIV201 in Phase 2A clinical trial for refractory ascites due to liver cirrhosis Source text for Eikon: Further company coverage:
perking right along. too early to say but i get the feeling this mgmt means business on both fronts.
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
84
|
Created
|
10/18/08
|
Type
|
Free
|
Moderators |
BKF Capital Group, Inc.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |